Drug intelligence / Profile preview

JW26

Development stage: Preclinical
Lead developer: Juventas Cell Therapy
Modality: Cell Therapies, Peptides
Administration: Topical

Overview

JW26 is a preclinical regenerative medicine candidate developed by Juventas Cell Therapy. It is a cell-based therapy that incorporates peptide components, specifically designed for the regeneration of periodontal ligaments (PDLs). The therapy leverages Juventas's cellular engineering platform to facilitate tissue repair and restoration in periodontal applications. While the company is primarily focused on CAR-T therapies for oncology, JW26 represents an expansion into the field of regenerative medicine, aiming to provide novel solutions for dental and ligament-related clinical needs.

Beyond the preview

Go deeper on JW26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW26.

Explore the full profile